Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nbqx SCHEMBL220464 | 0.81 | MAPT (0.74) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL29412437 | 0.81 | MAPT (0.74) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL30728067 | 0.80 | MAPT (0.73) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL26985644 | 0.80 | MAPT (0.73) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| Nbqx SCHEMBL2230845 | 0.75 | MAPT (0.65) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL14149481 | 0.74 | TDP1 (0.64) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL28120662 | 0.73 | KMT2A (0.61) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL5142239 | 0.73 | CDK2 (0.56) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL9341166 | 0.71 | KMT2A (0.61) | MAPTKDM4EKMT2AHPGDHSD17B10 | |
| SCHEMBL7534908 | 0.70 | GPR35 (0.62) | MAPTKDM4EKMT2AHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1586321-B1 | New use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2008-12-10 | — | — | EP | claimed |
| US-7101879-B2 | Treatments for neurotoxicity in Alzheimer's Disease | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-09-05 | — | — | US | claimed |
| EP-1015013-A4 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2002-07-24 | — | — | EP | claimed |
| US-6172043-B1 | GENETIC ENGINEERED POLYPEPTIDE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-01-09 | — | — | US | claimed |
| EP-1015013-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998030229-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-07-16 | — | — | WO | claimed |
| EP-1474126-A4 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7101879-B2 | Treatments for neurotoxicity in Alzheimer's Disease | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-09-05 | — | — | US | disclosed |
| US-7067550-B2 | Treatments for neurotoxicity in Alzheimer's Disease | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-06-27 | — | — | US | disclosed |
| EP-1341548-A4 | METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY $g(b)-AMYLOID PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6942963-B1 | Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1474126-A2 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| US-20030114510-A1 | Treatments for neurotoxicity in alzheimer's disease | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2003-06-19 | — | — | US | disclosed |
| US-20030105152-A1 | Treatments for neurotoxicity in Alzheimer's disease | INSTITUTE OF TECHNOLOGY, MASSACHUSETTS | 2003-06-05 | — | — | US | disclosed |
| EP-1015013-A4 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INST TECHNOLOGY (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002035987-A2 | METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-10 | — | — | WO | disclosed |
| US-6172043-B1 | GENETIC ENGINEERED POLYPEPTIDE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-01-09 | — | — | US | disclosed |
| EP-1015013-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998030229-A1 | TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | MAPT 619/4885KDM4E 1872/4885KMT2A 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.